Efficiency and safety of recombinant activated factor VII in a case of severe postpartum hemorrhage;Efficacité et tolérance du facteur VIIa recombinant dans l'hémorragie grave du post-partum: à propos d'un cas et revue de la littérature

Annales Francaises d'Anesthesie et de Reanimation

Volumn 29, Issue 10, 2010, Pages 728-731

  Geiger, A ^a   Collange, O ^a   Samin, J ^a   Meyer, A ^a   Freys, G ^a   Pottecher, T ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Postpartum hemorrhage; Recombinant activated factor VII; Risk benefit ratio

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART ARREST; HUMAN; LEG ISCHEMIA; LUNG EMBOLISM; POSTPARTUM HEMORRHAGE;

ADULT; FACTOR VIIA; FEMALE; HUMANS; POSTPARTUM HEMORRHAGE; RECOMBINANT PROTEINS; SAFETY; SEVERITY OF ILLNESS INDEX;

EID: 77957758821     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annfar.2010.05.004     Document Type: Article

References (21)

1. Lalonde A., Daviss B.A., Acosta A., Herschderfer K. Postpartum haemorrhage today: ICM/FIGO initiative 2004-2006. Int J Gynaecol Obstet 2006, 94:243-253.
2. Institut de veille sanitaire, bulletin épidémiologique hebdomadaire, mortalité maternelle en France. (consulté le 07/03/2009). http://www.invs.sante.fr/beh/2006/50/beh_50_2006.pdf.
3. Hémorragies du post-partum immédiat. Recommandations pour la pratique clinique. (consulté le 21/08/2009). http://www.cngof.asso.fr/D_PAGES/PURPC_12.HTM.
4. Vincent J.L., Rossaint R., Riou B., Ozier Y., Zideman D., Spahn D.R. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective. Crit Care 2006, 10:R120.
5. Réferentiel de bon usage, commission d'autorisation de mise sur le marché des médicaments. Protocoles thérapeutiques temporaires (en ligne). Disponible sur: (consulté le 03/08/2008). http://afssaps.sante.fr/htm/1/camm/cr-amm-071202.pdf.
6. Moscado F., Perez F., De La Rubia J., Balerdi B., Lorenzo J.I., Senent M.L., et al. Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII. Br J Haematol 2001, 113:174-176.
7. Ahonen J., Jokela R. Recombinant factor VIIa for life-threatening postpartum haemorrhage. Br J Anaesth 2005, 94:592-595.
8. Ahonen J., Jokela R., Korttila K. An open non-randomized study of recombinant activated factor VII in major postpartum haemorrhage. Acta Anaesthesiol Scand 2007, 51:929-936.
9. Brice A., Hilbert U., Roger-Christoph S., Fernandez H., Dumenil A.S., Descorps-Declère A., et al. Intérêt du facteur VII activé recombinant dans l'hémorragie de la délivrance sévère réfractaire à la prise en charge conservatrice conventionnelle. Ann Fr Anesth Reanim 2004, 23:1084-1088.
10. Haynes J., Laffan M., Plaat F. Use of recombinant activated factor VII in massive obstetric haemorrhage. Int J Obstet Anest 2007, 16:40-49.
11. Alfirevic Z., Elbourne D., Pavord S., Bolte A., Van Geijn H., Mercier F. Use of recombinant activated factor VII in primary postpartum hemorrhage: the Northern European registry 2000-2004. Obstet Gynecol 2007, 110:1270-1278.
12. Martinowitz U., Michaelson M. Guidelines for the use of recombinant activated factor VII (rfVIIa) in uncontrolled bleeding: a report by the Israeli multidisciplinary rfVIIa task force. J Thromb Haemost 2005, 3:640-648.
13. Meng Z.H., Wolberg A.S., Monroe D.M., Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003, 55:886-891.
14. Karalapillai D., Popham P. Recombinant factor VIIa in massive postpartum haemorrhage. Int J Obstet Anest 2007, 16:29-34.
15. Loudon B., Smith M.P. Recombinant factor VIIa as an adjunctive therapy for patients requiring large volume transfusion: a pharmacoeconomic evaluation. Intern Med J 2005, 35:463-467.
16. Plaat F. Recombinant factor VIIa should be used in massive obstetric haemorrhage. Int J Obstet Anesth 2007, 16:354-357.
17. Friederich P.W., Henny C.P., Messelink E.J., Geerdink M.G., Keller T., Kurth K.H., et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003, 361:201-205.
18. Mayer S.A., Brun N.C., Begtrup K., Broderick J., Davis S., Diringer M.N., et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005, 352:777-785.
19. ®): indications et limites. Reanimation 2006, 15:576-583.
20. O'Connell K.A., Wood J.J., Wise R.P., Lozier J.N., Braun M.M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006, 295:293-298.
21. Boyer-Neumann C. Hémostase et grossesse. EMC - Hématologie 2005, 2:132-140.